Lecithin as a therapeutic agent in Ulcerative Colitis
Lecithin [phosphatidylcholine (PC)] was shown to account for more than 70% of total phospholipids within the intestinal mucus layer. It is arranged in lamellar membranes (surfactant-like particles) and establishes a hydrophobic barrier preventing invasion of the colonic commensal microbiota. In ulce...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2013
|
| In: |
Digestive diseases
Year: 2013, Volume: 31, Issue: 3-4, Pages: 388-390 |
| ISSN: | 1421-9875 |
| DOI: | 10.1159/000354707 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000354707 Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/354707 
|
| Author Notes: | Wolfgang Stremmel, Annika Gauss |
| Summary: | Lecithin [phosphatidylcholine (PC)] was shown to account for more than 70% of total phospholipids within the intestinal mucus layer. It is arranged in lamellar membranes (surfactant-like particles) and establishes a hydrophobic barrier preventing invasion of the colonic commensal microbiota. In ulcerative colitis (UC), the mucus PC content was demonstrated to be reduced by about 70%, irrespective of the presence of inflammation. This may be of primary pathogenetic significance allowing bacteria to enter the mucus and induce mucosal inflammation. Therefore, a new therapeutic strategy is being developed to substitute the missing mucus PC content in UC. Indeed, a delayed-release PC formulation was able to compensate the lack of PC and improve the inflammatory activity. In randomized controlled studies, delayed-release PC was proven to be clinically and endoscopically effective, which now awaits a phase III authority approval trial. |
|---|---|
| Item Description: | Gesehen am 15.03.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1421-9875 |
| DOI: | 10.1159/000354707 |